Sequenom and Isis to Collaborate on SNP Research
By Biotechdaily staff writers
Posted on 21 Apr 2003
An agreement to collaborate in research to discover single nucleotide polymorphisms (SNPs) in antisense drug target regions has been announced by Sequenom, Inc. (San Diego, CA, USA) and Isis Pharmaceuticals, Inc. (Carlsbad, CA, USA). Posted on 21 Apr 2003
Using antisense oligonucleotide binding regions on mRNA targets identified by Isis' internal research programs, Sequenom will use its re-sequencing technology and its large collection of ethnically diverse DNA samples to find naturally occurring variations with the target regions in the general population. Uncovering both common and rare SNPs will guide final target region selection and help ensure that the future antisense drugs of Isis are broadly applicable for the general population.
"This application represents a novel use for our MassARRAY technology-based SNP Discovery application, which we recently introduced with our re-sequencing technology,” said Toni Schuh, Ph.D., president and CEO of Sequenom. "We believe this is a great example of how MassARRAY technology can be used in virtually any applications where high-performance, accurate DNA analysis is critical.”
Related Links:
Sequenom
Isis Pharma
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
